Method for analyzing PSA, and a method for distinguishing prostate cancer from prostatic hypertrophy using that method for analyzing PSA
View Patent ↗A method for distinguishing prostate cancer from prostatic hypertrophy using the method for analyzing PSA and an analysis kit of PSA are provided. An object of the present invention can be solved by being brought into contact a lectin having an affinity for β-N-acetylgalactosamine residues with a sample possibly containing PSA, to determine an amount of PSA having an affinity for the lectin. A method for distinguishing prostate cancer from prostatic hypertrophy can be provided by this method.
1. A method for determining an amount, if any, of PSA having a β-N-acetylgalactosamine residue and/or a sialic acid α(2,6) β-N-acetylgalactosamine residue in a sample, comprising the following step of
(a) adding a sialidase to a sample possibly containing PSA, to obtain the sialidase-treated sample;
(b) determining an amount of PSA having β-N-acetylgalactosamine residue in the sialidase-treated sample by an immunoassay using an antibody specific to PSA and a lectin having an affinity for β-N-acetylgalactosamine residue.
2. The method for determining an amount, if any of PSA having a β-N-acetylgalactosamine residue and/or a sialic acid α(2,6) β-N-acetylgalactosamine residue, comprising the steps of
(a) adding sialidase to a sample possibly containing PSA, to obtain the sialidase-treated sample;
(b) bringing into contact a lectin having an affinity for a β-N-acetylgalactosamine residue with the sialidase-treated sample, to separate into a bound fraction PSA having a β-N-acetylgalactosamine residue from a nonbound fraction of PSA lacking a β-N-acetylgalactosamine residue;
(c) determining an amount of PSA having a β-N-acetylgalactosamine residue in the sialidase-treated sample of the bound fraction by an immunoassay using an antibody specific to PSA and a lectin having an affinity for β-N-acetylgalactosamine residue, or antibodies specific to PSA.
3. The method for determining an amount, if any, of PSA having a β-N-acetylgalactosamine residue and/or a sialic acid α(2,6) β-N-acetylgalactosamine residue according to claim 2 , wherein the amount of PSA having β-N-acetylgalactosamine residue and a sialic acid α(2,6) β-N-acetylgalactosamine residue is determined
(1) by measuring an amount of separated PSA having β-N-acetylgalactosamine residue in the bound fraction using an antibody specific to PSA and a lectin having an affinity for β-N-acetylgalactosamine residue, or antibodies specific to PSA,
(2) by measuring an amount of PSA in a sample before the separation using antibodies specific to PSA, and measuring an amount of the separated PSA having β-N-acetylgalactosamine residue in the bound fraction using an antibody specific to PSA and a lectin having an affinity for β-N-acetylgalactosamine residue or antibodies specific to PSA, or
(3) by measuring an amount of PSA in a sample before the separation using antibodies specific to PSA, and measuring an amount of the separated PSA lacking β-N-acetylgalactosamine residue in the nonbound fraction using antibodies specific to PSA.
4. The method for determining an amount, if any, of PSA having a β-N-acetylgalactosamine residue and/or a sialic acid α(2,6) β-N-acetylgalactosamine residue according to claim 3 , wherein the amount of PSA having β-N-acetylgalactosamine residue is determined by measuring total PSA or free PSA.
5. The method for determining an amount, if any, of PSA having a β-N-acetylgalactosamine residue and/or a sialic acid α(2,6) β-N-acetylgalactosamine residue according to claim 1 , wherein the lectin is Trichosanthes japonica agglutinin-II or Wisteria floribunda agglutinin.
6. The method for determining an amount, if any, of PSA having a β-N-acetylgalactosamine residue and/or a sialic acid α(2,6) β-N-acetylgalactosamine residue according to claim 1 , wherein the lectin further has an affinity for fucose α(1,2) galactose residue.
7. The method for determining an amount, if any, of PSA having a β-N-acetylgalactosamine residue and/or a sialic acid α(2,6) β-N-acetylgalactosamine residue according to claim 1 , wherein the sample is obtained from a patient suspected of having prostate cancer.